Median effective dose of oxycodone inhibiting responses to laryngeal mask airway insertion when combined with propofol in adult female patients
10.3760/cma.j.issn.0254-1416.2018.05.014
- VernacularTitle:复合丙泊酚时羟考酮抑制成年女性患者喉罩置入反应的半数有效剂量
- Author:
Ying LUO
1
;
Yang YU
;
Xiaolian ZHOU
;
Zhengwei YU
;
Hongmei ZHAO
;
Jianliang SUN
Author Information
1. 310006,浙江大学医学院附属杭州市第一人民医院麻醉科
- Keywords:
Oxycodone;
Laryngeal mask;
Dose-response relationship,drug;
Propofol;
Adult;
Female
- From:
Chinese Journal of Anesthesiology
2018;38(5):562-564
- CountryChina
- Language:Chinese
-
Abstract:
Objective To determine the median effective dose (ED50) of oxycodone inhibiting responses to laryngeal mask airway (LMA) insertion when combined with propofol in the adult female patients.Methods Female patients,aged 18-60 yr,with body mass index of 18-24 kg/m2,of American Society of Anesthesiologists physical status Ⅰ or Ⅱ,scheduled for elective gynecologic surgery,were included.ED50 of oxycodone was determined by up-and-down sequential technique.Anesthesia was induced by target-controlled infusion of propofol at target plasma concentration of 3.0 μg/ml.Oxycodone was injected at the initial dose of 0.11 mg/kg after the target effect-site and plasma concentrations were balanced.LMA was inserted at 5 min following injection.When the response to LMA insertion was positive,the concentration of oxycodone was increased/decreased in the next patient.The difference between the two successive doses was 0.02 mg/kg.LMA insertion response was defined as occurrence of swallowing,biting on the LMA and bucking and/or body movement during insertion.Probit analysis was used to calculate the ED50 and 95％ confidence interval of oxycodone inhibiting responses to LMA insertion when combined with propofol.Results The ED50 (95％ confidence interval) of oxycodone inhibiting responses to LMA insertion was 0.095 (0.080-0.108) mg/kg when combined with propofol.Conclusion The ED50 of oxycodone inhibiting responses to LMA insertion is 0.095 mg/kg when combined with propofol in the adult female patients.
